ONCSQ (OncoSec Medical) Buyback Yield %: 0.00 (As of Jul. 01, 2026)


What is OncoSec Medical Buyback Yield %?

OncoSec Medical ONCSQ -99.00% Buyback Yield % is 0.00 as of Jul. 01, 2026.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

OncoSec Medical's current buyback yield was 0.00%.

OncoSec Medical Buyback Yield % Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical Buyback Yield % Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.70 -117.72 -30.98 -73.61 0.00

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ONCSQ vs NOVNQ, USRM, VRTX: Buyback Yield % Comparison

For the Biotechnology subindustry, OncoSec Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSec Medical Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Buyback Yield % falls into.


OncoSec Medical Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

OncoSec Medical's Buyback Yield for the fiscal year that ended in Jul. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 28.36147421
=0.00%

OncoSec Medical's annualized Buyback Yield for the quarter that ended in Jan. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 6.5362
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
OncoSec Medical (ONCSQ) has a Buyback Yield % of 0.00 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OncoSec Medical and its competitors.
Is OncoSec Medical's Buyback Yield % too high?
OncoSec Medical's current Buyback Yield % is 0.00.
How does OncoSec Medical's Buyback Yield % compare to NOVNQ and USRM?
OncoSec Medical's Buyback Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on OncoSec Medical and its competitors. OncoSec Medical's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current Buyback Yield % is 0.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.